USTR's new Section 301 investigation targeting Germany's drug pricing, combined with Section 232 pharmaceutical tariffs, signals a coordinated multistatute trade strategy.
| less than a minute read
Germany in the Crosshairs: USTR’s New Section 301 Drug Pricing Investigation and What It Means Alongside the Section 232 Pharmaceutical Tariff Regime
Get in touch
Get in touch
Get in touch
Get in touch
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-17-31-05-370-6a7dff59254a1a438c04847f.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-17-30-24-631-6a7dff305d5875e92599b3bd.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-13-11-12-930-6a7dc270226bd6f89e20adbb.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-08-13-13-10-12-561-6a7dc234ab75b4d21322f54f.jpg)